What is Supernus Pharmaceuticals, Inc. worth?
With the base-case assumptions below, a discounted cash flow model on Supernus Pharmaceuticals, Inc.'s reported free cash flow gives $19.46 per share. The share price was $42.66 on September 25, 2026, 119% above that value.
Inputs from the filings
Three sets of assumptions
| Case | Growth yrs 1-5 | Discount rate | Value per share | Value vs price |
|---|---|---|---|---|
| Bear | 1.5% | 10.0% | $13.36 | -69% |
| Base | 6.5% | 9.0% | $19.46 | -54% |
| Bull | 11.5% | 8.0% | $31.62 | -26% |
Sensitivity: base case value per share
| 1.5% | 2.0% | 2.5% | 3.0% | 3.5% | |
|---|---|---|---|---|---|
| 7.0% | $23.96 | $25.34 | $27.02 | $29.12 | $31.83 |
| 8.0% | $20.60 | $21.49 | $22.55 | $23.81 | $25.36 |
| 9.0% | $18.14 | $18.75 | $19.46 | $20.28 | $21.25 |
| 10.0% | $16.27 | $16.71 | $17.20 | $17.76 | $18.41 |
| 11.0% | $14.80 | $15.12 | $15.47 | $15.87 | $16.33 |
Where the presets come from
Base: years 1 to 5 grow at Supernus Pharmaceuticals, Inc.'s revenue growth rate over the last 5 fiscal years (6.7% a year), held between -5% and 15%. Years 6 to 10 grow halfway between that and the long-run rate of 2.5%. Future cash is discounted at 9% a year.
Bear: 5 points less growth, 2% long-run growth, 10% discount rate. Bull: 5 points more growth (at most 25%), 3% long-run growth, 8% discount rate.
Value per share = (present value of 10 years of free cash flow + present value of everything after + cash - debt) / diluted shares.
This is a model run on assumptions, not a recommendation or a price target. Small changes in the discount rate or growth move the result a lot, as the table above shows. Change them yourself in the calculator.
Adjust the assumptions
Move the sliders for growth, long-run growth and discount rate, or switch to average free cash flow, and see the value per share change.
Adjust the assumptions